Facts
as of Nov 17, 2026
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients.
It is hiring: 3 open roles, 1 of them posted in the last 30 days.
- Legal name
- Prelude Therapeutics Inc.
- Headquarters
- Newark, United States
- Founded
- 2016
- Employees
- 201-500estimated range
- Open roles
- 3Alion job postings
- Register numbers
- NAME prelude therapeutics inc
- Website
- preludetx.com
As of Nov 17, 2026, Alion lists 3 open roles at Prelude Therapeutics. Prelude Therapeutics is headquartered in Newark, United States. It was founded in 2016. It has raised $115M in 4 funding rounds. The latest round is Venture - Series Unknown of $50M, announced in 2020.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Legal entity active
Prelude Therapeutics Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Hiring steadily, with new roles every week.
Biotech is the largest family, 100 of open roles.
1Posted in 30 days33% of open roles are fresh
0%Remote roles0 of 3
1Hiring offices
Can they hire you from United States?by your location
Likely
3 open roles are in your country: you apply locally, no move needed.
United States3On site
Remote, from elsewhere0Rare
No posting offers visa sponsorship. Remote roles: 0.
Alion signals0-100
Demand9
Pay9
Your chance44
How badly they need people, whether they pay, how realistic getting in is.
Where the openings areshare of open roles · trend
Newest roles
Clinical Trial Manager≈ $102k – $178k per year (Estimated) · In office · 7+ years exp · Bachelor's Degree · Wilmington
VP, Regulatory Affairs≈ $131k – $258k per year (Estimated) · In office · 15+ years exp · Master's Degree · Wilmington
What postings ask forlanguages named in open roles
Degree asked
Master's Degree 100%
2 postings state a degree.
Benefits named in postingsshare of open roles
Professional development150%
Visa sponsorship: none statedRelocation: none stated
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family
Named in the work visa registers of United States.
0H-1B filings in 12 months
3Open roles in United States
In the register as Prelude Therapeutics, Inc., Wilmington, DE
Other sponsors in the same field
US Department of Labor · latest filing Mar 5, 2025
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
WilmingtonBusiest site
Source: office addresses in postings and company registers
Financials
Funding rounds, investors and revenue on record.
$115MTotal raised
Venture - Series UnknownLatest round
4Rounds and grants
Money by yearUSD, rounds and grants
2020$50M1 record
2019$30M1 record
2017$30M1 record
2016$5M1 record
Largest rounds and grants
Sources: funding announcements, grant and company registers
Tech stack
Technologies named in job postings at Prelude Therapeutics over the last 12 months, by layer, with the share of postings for each.
4Technologies in use
2Postings analysed
53/100Stack modernity
Sign in to see how your skills match this stackSign In
Source: the technologies named in the company's postings and on its site
Milestones
Each milestone is dated by its source: registers, filings, the press
Newsroom
Oct 72026
Blog
Ryan Holmes, Associate Director, Chemistry on behalf of the DAC team The post Precision Degrader Antibody Conjugates (DACs): An Emerging Modality in Targeted Therapeutics appeare…
Sep 232026
News · Prelude Therapeutics stock falls 9.9 percent despite FDA progress
Prelude Therapeutics stock traded at USD 4.37 on Nasdaq on September 23, 2026, while Q2 revenue reached USD 5.7 million. Q2 net loss was USD 13.9 million.
Sep 202026
News · Prelude Therapeutics stock gains as FDA clears new breast cancer drug trial
Prelude Therapeutics stock has risen strongly in recent weeks after FDA clearance of the IND for breast cancer candidate PRT13722, with shares closing at USD 4.87 on September 18…
Sep 102026
News · YahooFinance
Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth quarter of 2026.WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIR…
Aug 222026
News · Pulse 2.0
Prelude Therapeutics reduced its second-quarter 2026 net loss by approximately 55% year-over-year as research and development spending declined sharply following the pausing of p…
Jul 222026
Blog
Ryan Holmes, Andrew Moore, Max Foroutan, Jake Karwoski, Alex Grego, Carly Bachner1 Neha Bhagawat, Corey Basch, Soham Maity, Chun Chen, Sarah B. Pawley, Vijay Devannah, Sina Rezaz…
Sources: the outlets named on each headline, each story once